July 11, 2018
New funding for the Canadian Cancer Clinical Trials Network will help more cancer patients access clinical trials
Toronto (July 11, 2018) – The Ontario Institute for Cancer Research (OICR) and the Canadian Partnership Against Cancer (the Partnership) today announced renewed funding for the Canadian Cancer Clinical Trials Network (3CTN). The funding will ensure Canada remains a world leader in academic cancer clinical trials, help to increase opportunities for patients to receive promising new treatments and continue to improve outcomes for cancer patients through research.
June 14, 2018
New OICR President and Scientific Director comments on breakthrough in breast cancer T-cell immunotherapy
For the first time, a patient’s late-stage breast cancer has been successfully treated with T-cell immunotherapy. This cutting-edge approach, which is currently in clinical trials in the U.S., modified the patient’s naturally-occurring immune cells to fight her tumours that had spread throughout her body. The patient has been cancer free for the past two years and her remarkable tumour regression represents the potential impact of this new immunotherapeutic approach.
March 6, 2018
VANCOUVER – Canadian pancreatic cancer researchers are joining forces under a Terry Fox initiative bringing new hope for patients with this deadly disease.
“For many years it’s been hopeless from a patient perspective, and we are hoping to help shift this,” says Dr. Daniel Renouf (BC Cancer, University of British Columbia) who, along with Dr. David Schaeffer (UBC, Vancouver General Hospital), is leading a $5-million pan-Canadian, precision medicine initiative recently funded by the Terry Fox Research Institute.
A lack of early detection tests. Few known symptoms. Very limited treatment options. No known biomarkers that can be used to direct therapy. These are among the clinical challenges team EPPIC, short for Enhanced Pancreatic Cancer Profiling for Individualized Care, is tackling over the next five years to improve personalized treatments for patients with pancreatic ductal adenocarcinoma (PDAC), a disease with just a nine per cent five-year survival rate.
January 30, 2018
Early results from COMPASS trial demonstrate benefits of using genomic sequencing to guide treatment for pancreatic cancer
Genomic profiling has allowed physicians to customize treatments for patients with many types of cancer, but bringing this technology to bear against advanced pancreatic cancer has proven to be extremely difficult. OICR’s pancreatic cancer Translational Research Initiative, called PanCuRx, has been conducting a first-of-its-kind clinical trial called COMPASS to evaluate the feasibility of using real time genomic sequencing in pancreatic cancer care. The research team recently reported early results from the trial, which show how they overcame the challenges of genomic profiling specific to pancreatic cancer and gained new insights about the disease.
PanCuRx is focused on improving treatment for pancreatic adenocarcinoma (PDAC), the most common form of pancreatic cancer and the fourth leading cause of cancer death in Canada. The group’s approach centres around understanding the genetics and biology of PDAC to inform the selection of therapies, as well as the development of new treatments.
September 6, 2017
Toronto (September 6, 2017) – Understanding a cancer’s genetics is key to selecting targeted therapies that are likely to be of the most benefit to a patient. The Ontario Institute for Cancer Research (OICR) today announced a new study, called Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE). OCTANE will use next-generation genome sequencing technology to bring a unified molecular profiling approach to five Ontario cancer centres.
May 3, 2017
The advent of genomic sequencing and targeted therapies has opened the door to new ways of diagnosing and treating cancer. The Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) program is a new, province-wide initiative supported by OICR that will allow more patients to benefit from these innovations while also helping to advance cancer research in Ontario.
April 26, 2017
The first patient has been treated in what has been named the Sandpiper Trial. The Phase I/II clinical trial will evaluate a therapy that combines a novel oncolytic viral immunotherapy agent called MG1-MAGEA3 with pembrolizumab, which is an approved checkpoint inhibitor. The Sandpiper Trial will study the use of this combination therapy in patients with non-small cell lung cancer who are no longer responding to chemotherapy.
November 2, 2016
OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies
TORONTO, Nov. 2, 2016 /CNW/ – Turnstone Biologics Inc. (“Turnstone”), an Ontario-based developer of novel oncolytic viral immunotherapies, announced the closing of a USD $41.4 million Series B financing led by OrbiMed Advisors LLC (“OrbiMed”) and Versant Ventures (“Versant”), which led Turnstone’s Series A round in October 2015. New investor F-Prime Capital Partners (“F-Prime”) and existing founding investor FACIT also participated. Proceeds from the financing will support an ongoing Phase I/II clinical trial in patients with advanced or metastatic solid tumours as well as accelerate and expand Turnstone’s pipeline, funding the development of three additional programs into the clinic. In connection with the financing Orbimed’s Rishi Gupta, JD and F-Prime’s Ben Auspitz will join Turnstone’s board of directors alongside Versant’s Brad Bolzon, PhD and Jerel Davis, PhD as well as FACIT’s Jeff Courtney.
October 21, 2016
OICR-led study finds four unique genomic signatures in pancreas cancer, uncovers potential of immunotherapies
Pancreas cancer is one of the most aggressive and deadly forms of the disease. According to the Canadian Cancer Society, only 8 percent of pancreas cancer patients survive more than five years after diagnosis. OICR’s PanCuRx Translational Research Initiative has recently published the results of an international collaboration that increases understanding of this complex disease and how to treat it based on a patient’s unique profile.
June 21, 2016
Cancer drugs help millions of people every year by assisting them in living longer or by reducing side effects or symptoms. In some cases, cancer drugs can even prevent cancers from developing. But cancer drugs take a long time to carefully develop and test, and the process is expensive. We asked Dr. David Uehling, Scientific Advisor and Group Leader, Medicinal Chemistry Group in the Drug Discovery Program at OICR, to help explain the process and its challenges.
June 1, 2016
Dr. Laurence Klotz of Sunnybrook Health Sciences Centre is a world leader in the field of prostate cancer research. He has been a champion of active surveillance (also known as watchful waiting) for over 20 years, an approach to prostate cancer treatment that has allowed thousands of men with low-risk prostate cancer to avoid or delay therapy by monitoring it closely instead of immediately treating it.
Now Klotz has launched a new clinical trial called PRECISE, funded with $3 million in support by the Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada, that will use MRI to help to better diagnose prostate cancer without invasive biopsy.
June 1, 2016
Research supported by the Movember Foundation, the Ontario Institute for Cancer Research and Prostate Cancer Canada
Toronto, ON – June 1, 2016 – The Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects.
The trial will be led by Dr. Laurence Klotz of the Sunnybrook Research Institute in Toronto, a world leader in the field of prostate cancer research and in the global adoption of active surveillance, a standard practice to monitor patients with low risk prostate cancer.